The estimated Net Worth of Christopher J. Kirk is at least $2.19 Milion dollars as of 20 July 2023. Christopher Kirk owns over 48,950 units of Kezar Life Sciences Inc stock worth over $250,182 and over the last 6 years he sold KZR stock worth over $0. In addition, he makes $1,942,330 as President, Chief Scientific Officer a Director at Kezar Life Sciences Inc.
Sign up
Christopher Kirk KZR stock SEC Form 4 insiders trading
Christopher has made over 5 trades of the Kezar Life Sciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 48,950 units of KZR stock worth $44,055 on 20 July 2023.
The largest trade he's ever made was exercising 48,950 units of Kezar Life Sciences Inc stock on 20 July 2023 worth over $44,055. On average, Christopher trades about 10,036 units every 111 days since 2018. As of 20 July 2023 he still owns at least 431,348 units of Kezar Life Sciences Inc stock.
You can see the complete history of Christopher Kirk stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Kirk biography
Dr. Christopher Kirk Ph.D. serves as President, Chief Scientific Officer, Director of the Company. Prior to founding our company, Dr. Kirk was the Vice President of Research at Onyx Pharmaceuticals, Inc., from April 2010 to April 2014. Dr. Kirk previously served as Director of Pharmacology and Biology at Onyx Pharmaceuticals and at Proteolix, Inc. Dr. Kirk has served as a member of the Scientific Advisory Board at Karyopharm Therapeutics, Inc., C4 Therapeutics, Inc. and Avidity Biosciences LLC. Dr. Kirk received his B.S. degree in biochemistry from the University of California, Davis, and his Ph.D. degree in cellular and molecular biology from the University of Michigan. Kirk’s extensive knowledge of our company as co-founder and his experience at pharmaceutical companies and his scientific experience and achievements qualifies him to serve on our Board.
What is the salary of Christopher Kirk?
As the President, Chief Scientific Officer a Director of Kezar Life Sciences Inc, the total compensation of Christopher Kirk at Kezar Life Sciences Inc is $1,942,330. There are 1 executives at Kezar Life Sciences Inc getting paid more, with John Fowler having the highest compensation of $3,532,020.
How old is Christopher Kirk?
Christopher Kirk is 48, he's been the President, Chief Scientific Officer a Director of Kezar Life Sciences Inc since 2015. There are 10 older and 3 younger executives at Kezar Life Sciences Inc. The oldest executive at Kezar Life Sciences Inc is Franklin Berger, 70, who is the Independent Director.
What's Christopher Kirk's mailing address?
Christopher's mailing address filed with the SEC is C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Kezar Life Sciences Inc
Over the last 6 years, insiders at Kezar Life Sciences Inc have traded over $3,836,099 worth of Kezar Life Sciences Inc stock and bought 6,372,267 units worth $30,891,130 . The most active insiders traders include Venture Investments Ltd Mor..., Asset Management, Lp Chen B... a Franklin M Berger. On average, Kezar Life Sciences Inc executives and independent directors trade stock every 49 days with the average trade being worth of $91,954. The most recent stock trade was executed by Mark C. Schiller on 2 July 2024, trading 6,688 units of KZR stock currently worth $3,879.
What does Kezar Life Sciences Inc do?
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
What does Kezar Life Sciences Inc's logo look like?
Complete history of Christopher Kirk stock trades at Kezar Life Sciences Inc
Kezar Life Sciences Inc executives and stock owners
Kezar Life Sciences Inc executives and other stock owners filed with the SEC include:
-
John Fowler,
Chief Executive Officer, Director -
Christopher Kirk,
President, Chief Scientific Officer, Director -
Marc Belsky,
Chief Financial Officer, Secretary -
John Franklin Fowler,
Co-Founder, CEO & Director -
Dr. Noreen Roth Henig,
Chief Medical Officer -
Dr. Christopher J. Kirk,
Co-Founder, Pres, Chief Scientific Officer & Director -
Jean-Pierre Sommadossi,
Independent Chairman of the Board -
Graham Cooper,
Independent Director -
Michael Kauffman,
Independent Director -
Franklin Berger,
Independent Director -
Jason Dinges,
Independent Director -
Elizabeth Garner,
Independent Director -
Alex Gray,
IR Contact Officer -
Noreen Henig,
Chief Medical Officer -
Vassiliki Economides,
Senior Vice President - Strategy and External Affairs -
Vassiliki Economides,
Sr. VP of Strategy & External Affairs -
Gitanjali Jain,
VP of Investor Relations & External Affairs -
Michael Wolfe,
Director of Fin. & Operations -
Marc L. Belsky,
CFO & Sec. -
Dr. Jack Taunton Ph.D.,
Co-Founder -
Talent Investments Ltd Equal,
10% owner -
Management Company, Llc Abe...,
10% owner -
Arthur Ma.M. Pappas Life Sc...,
-
Fund Iv, L.P.Omega Fund Iv ...,
-
Asset Management, Lp Chen B...,
-
Venture Investments Ltd Mor...,
-
Ventures, Inc.Chiesi Ventur...,
-
Therapeutics, Inc.Amgen Inc...,
-
City Capital Llc Bay,
10% owner -
Thomas F Steyer,
-
Niti Goel,
Chief Medical Officer -
Mark C. Schiller,
Chief Legal Officer -
Nicholas Michael Mordwinkin,
Chief Business Officer -
Micki Klearman,
-
Courtney Wallace,